Abstract

Chondrocyte hypertrophy is one of the key indicators in the progression of osteoarthritis (OA). However, compared with other OA indications, such as cartilage collapse, sclerosis, inflammation, and protease activation, the mechanisms by which chondrocyte hypertrophy contributes to OA remain elusive. As the pathological processes in the OA cartilage microenvironment, such as the alterations in the extracellular matrix, are initiated and dictated by the physiological state of the chondrocytes, in-depth knowledge of chondrocyte hypertrophy is necessary to enhance our understanding of the disease pathology and develop therapeutic agents. Chondrocyte hypertrophy is a factor that induces OA progression; it is also a crucial factor in the endochondral ossification. This review elaborates on this dual functionality of chondrocyte hypertrophy in OA progression and endochondral ossification through a description of the characteristics of various genes and signaling, their mechanism, and their distinguishable physiological effects. Chondrocyte hypertrophy in OA progression leads to a decrease in chondrogenic genes and destruction of cartilage tissue. However, in endochondral ossification, it represents an intermediate stage at the process of differentiation of chondrocytes into osteogenic cells. In addition, this review describes the current therapeutic strategies and their mechanisms, involving genes, proteins, cytokines, small molecules, three-dimensional environments, or exosomes, against the OA induced by chondrocyte hypertrophy. Finally, this review proposes that the contrasting roles of chondrocyte hypertrophy are essential for both OA progression and endochondral ossification, and that this cellular process may be targeted to develop OA therapeutics.

Highlights

  • Osteoarthritis (OA) is one of the most common chronic diseases worldwide

  • It was shown that parathyroid hormone-related protein (PTHrP) targets and activates Histone Deacetylase 4 (HDAC4) and HDAC5 to suppress myocyte enhancer factor 2 (MEF2), which is required for the expression of RUNX2, a marker of chondrocyte hypertrophy [112]

  • These results clearly suggest that the use of PTHrP, alone or in conjunction with Mesenchymal stem cells (MSCs) differentiation, could be a good and reliable treatment approach to preventing chondrocyte hypertrophy

Read more

Summary

Introduction

Osteoarthritis (OA) is one of the most common chronic diseases worldwide. Globally, over 300 million people suffer from OA, which is accompanied by constant pain and cartilage degeneration [1]. The chronic pain of OA causes constant psychological stress and physical disability [3] Overcoming this disease is important for well-being in an aging modern society. As in any other cell, chondrocytes degenerate due to aging, excessive mechanical load, or disease complications, such as abnormal metabolism and autoimmune disorders [6]. Chondrocytes lose their functionality and secrete fibrous ECM components, such as collagen type I (COL1) and X (COL10), as well as ECM-degrading proteases, such as matrix metalloproteinase-13 (MMP13), disintegrin, and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), all of which promote OA. This review describes the recent trends in the treatment of OA related to chondrocyte hypertrophy, including genetic intervention and the application of biomolecules, chemical compounds, three-dimensional (3D) microenvironments, or exosomes

Chondrocyte Hypertrophy in Endochondral Ossification
Genetic Interventions against Chondrocyte Hypertrophy
TGF-β1
Inhibitors of Hypertrophic Markers
Small Molecules Preventing Chondrocyte Hypertrophy
Three-Dimensional Environments Preventing Chondrocyte Hypertrophy
Exosomes
Stem Cell-Derived Exosomes
Exosomes Derived from Other Cell Types
Findings
Conclusions and and Future
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call